What the Research Actually Says About EPA DHA Ratio

What the Research Actually Says About EPA DHA Ratio

Flip over almost any fish oil bottle and you'll see two numbers: EPA and DHA. Most people glance at the combined total and assume more is better. But an expanding body of research suggests that which fatty acid you emphasize — and in what proportion — can meaningfully change the outcomes you get from an omega-3 supplement.

EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are both long-chain omega-3 polyunsaturated fatty acids, yet they act through distinct biochemical pathways. EPA is a precursor to anti-inflammatory eicosanoids and resolvins; DHA is a structural component of cell membranes, particularly in the brain and retina. That functional difference is exactly why the ratio between them matters — and why researchers have spent the last two decades trying to pin down the ideal split for specific health conditions.

Why EPA and DHA Work Differently in the Body

Before diving into ratios, it helps to understand what each fatty acid actually does.

EPA's primary roles:

• Competes with arachidonic acid for cyclooxygenase (COX) enzymes, reducing pro-inflammatory prostaglandin E2 production
• Serves as a precursor to E-series resolvins, which actively resolve inflammation
• Modulates serotonin receptor sensitivity — a mechanism increasingly linked to mood regulation

DHA's primary roles:

• Structural integration into neuronal membranes, improving fluidity and synaptic signaling
• Precursor to D-series resolvins and neuroprotectins
• Preferentially concentrated in the retina, testes, and cerebral cortex
• Supports triglyceride clearance via VLDL metabolism

Because EPA and DHA have distinct tissue targets and metabolic fates, the "right" ratio depends heavily on your health goal. A ratio optimized for inflammation control is not necessarily the same ratio optimized for cognitive support — and the clinical data backs this up.

What Ratio of EPA to DHA Is Best for Inflammation?

For systemic inflammation, the research consistently favors EPA-predominant formulas. A landmark meta-analysis by Calder (Prostaglandins, Leukotrienes and Essential Fatty Acids, 2015; doi.org/10.1016/j.plefa.2014.10.002) reviewed evidence from randomized controlled trials and concluded that EPA, more than DHA, drives reductions in circulating inflammatory markers including C-reactive protein (CRP), interleukin-6 (IL-6), and TNF-α.

In head-to-head trials comparing pure EPA versus pure DHA supplementation, EPA consistently shows stronger suppression of arachidonic acid-derived eicosanoids. One 12-week RCT in healthy adults found that EPA supplementation (2 g/day) reduced plasma phospholipid arachidonic acid levels significantly more than an equivalent DHA dose (Yurko-Mauro et al., Nutrition Journal, 2015; doi.org/10.1186/s12937-015-0073-8).

For conditions characterized by chronic low-grade inflammation — think metabolic syndrome, elevated hs-CRP, or joint discomfort — a higher EPA:DHA ratio (roughly 2:1 to 3:1) appears to be the more evidence-aligned approach. If you're using omega-3s primarily to support healthy inflammatory balance, prioritizing EPA makes mechanistic and clinical sense.

If you're curious how omega-3 supplementation integrates with a broader anti-inflammatory protocol, the omega-3 EPA DHA ratio guide offers additional context on dosing and sourcing.

EPA DHA Ratio for Depression and Mental Health

The psychiatric literature has produced some of the most compelling ratio-specific data to date. The signal here is clear: for depression specifically, EPA — not DHA — appears to be the active driver of clinical benefit.

A systematic review and meta-analysis published in Translational Psychiatry (Liao et al., 2019; PMID: 31383846) analyzed 26 RCTs and found that omega-3 formulas in which EPA exceeded DHA were significantly more effective at reducing depressive symptoms than DHA-dominant or balanced formulas. Critically, formulas with EPA:DHA ratios below 1.5:1 showed no significant antidepressant effect in the pooled analysis.

Another widely cited meta-analysis (Sublette et al., Journal of Clinical Psychiatry, 2011; PMID: 21939614) found that only trials using omega-3 supplements containing at least 60% EPA (relative to combined EPA+DHA) showed a statistically significant reduction in depression scores. Trials using DHA-dominant formulas showed no benefit.

The proposed mechanism involves EPA's modulation of phospholipase A2 activity and eicosanoid production in the brain, as well as its influence on serotonin and dopamine neurotransmitter systems. DHA is essential for membrane structure, but in depression, it appears to be EPA that moves the needle.

Practical takeaway: for mood support, target an EPA:DHA ratio of at least 2:1, and many researchers advocate for 3:1 or higher. A total EPA intake of 1,000–2,000 mg/day is the range used in most successful antidepressant trials.

DHA-Dominant Ratios for Cognitive Health and Brain Development

Flip the logic for brain structure and you'll find a different picture. DHA makes up approximately 97% of the omega-3 fatty acids in the brain, concentrated in the prefrontal cortex and hippocampus. It's not that EPA doesn't matter for cognition — it does — but for structural brain support, DHA takes the lead.

A 6-month RCT published in Alzheimer's & Dementia (Quinn et al., 2010; PMID: 20434395) supplemented participants with 2 g/day DHA and found that higher DHA plasma levels correlated with slower cognitive decline in early Alzheimer's disease. Importantly, effect sizes were largest in individuals who were APOE4-negative.

For pregnant and lactating women, clinical guidelines from the European Food Safety Authority (EFSA Journal, 2012) recommend a supplemental DHA intake of at least 200 mg/day for fetal and infant brain development — independent of EPA. The Third Expert Consultation on Fats and Fatty Acids in Human Nutrition (FAO/WHO, 2010) supports a similar recommendation.

For older adults concerned about cognitive aging, a DHA-leaning ratio (roughly 1:2 EPA:DHA) or even pure DHA supplementation may be more appropriate than an EPA-dominant formula. This is one of the clearest examples of why personalization matters: the optimal omega-3 formula for a 35-year-old managing inflammation looks different from the formula for a 65-year-old focused on memory.

EPA DHA Ratio for Cardiovascular Health

Cardiovascular research has historically treated EPA and DHA as interchangeable — both lower triglycerides, both reduce platelet aggregation, both modestly improve endothelial function. But recent high-dose prescription trials have complicated this picture considerably.

The REDUCE-IT trial (Bhatt et al., New England Journal of Medicine, 2019; PMID: 30415628) used 4 g/day of pure EPA (icosapentaenoic acid ethyl ester — VASCEPA) in statin-treated patients with elevated triglycerides and found a 25% relative reduction in major adverse cardiovascular events versus placebo. This was a landmark result.

However, the STRENGTH trial (Nicholls et al., JAMA, 2020; PMID: 33185635) used a 4 g/day EPA+DHA formula (roughly 3:2 EPA:DHA) in a similar population and found no significant reduction in cardiovascular events compared to a corn oil placebo. The contrast between these two trials ignited a significant debate in cardiology about whether pure EPA has unique cardiovascular benefits that a blended EPA+DHA formula cannot replicate.

One leading hypothesis is that DHA actually raises LDL particle size (which is largely neutral to beneficial), but may partially attenuate some of EPA's cardiovascular protective mechanisms at very high doses. This remains contested. What's not contested: for triglyceride reduction specifically, both EPA and DHA are effective, and the American Heart Association recognizes prescription omega-3s as a class for hypertriglyceridemia (AHA Scientific Statement, Skulas-Ray et al., Circulation, 2019; doi.org/10.1161/CIR.0000000000000709).

For general cardiovascular wellness at supplement doses (1–2 g EPA+DHA/day), an EPA-predominant formula remains a reasonable default — but for anyone with clinically elevated triglycerides, working with a healthcare provider to evaluate prescription-strength options is strongly recommended.

You can explore how omega-3s work alongside other heart-protective nutrients in the context of heart health supplements and clinical evidence.

Does the EPA to DHA Ratio Change Based on Your Baseline Levels?

Yes — and this is where personalization becomes genuinely important. Your baseline omega-3 index (the percentage of EPA+DHA in red blood cell membranes) and your habitual dietary intake both influence how much of each fatty acid you actually need to supplement.

The omega-3 index, developed by Harris and von Schacky, is measured via a simple blood test and reflects long-term omega-3 status. An index below 4% is considered high-risk; 8–12% is considered optimal (Harris & von Schacky, Preventive Medicine, 2004; PMID: 15208005). People starting from a low index need more total EPA+DHA before fine-tuning the ratio becomes the priority.

Similarly, individuals who eat fatty fish (salmon, mackerel, sardines) 2–3 times per week already have meaningfully higher DHA status compared to non-fish eaters, since DHA is preferentially retained in tissues. For these individuals, an EPA-predominant supplement may close a gap without over-supplementing DHA. Vegans and vegetarians, who tend to have very low DHA status, may benefit from algae-derived DHA supplementation even if their primary health goal is inflammation control.

Clinical biomarkers — ideally an omega-3 index panel — provide far more actionable guidance than a label recommendation. This is a core reason personalized supplement platforms have become increasingly relevant.

What This Means for Your Formula

At Ones, omega-3 supplementation is not treated as a single default ingredient. The AI health practitioner analyzes your lab data (including lipid panels, inflammatory markers, and omega-3 index if available), wearable data, and stated health goals to determine whether EPA-dominant, DHA-dominant, or balanced omega-3 supplementation makes sense for your specific profile.

Here's how three Ones ingredients map to the research covered above:

For users with elevated CRP or mood-related goals, Ones formulas can skew toward EPA-dominant omega-3 dosing. For users with cognitive aging concerns or those flagged as potentially DHA-deficient, DHA weighting is adjusted accordingly. If your cardiovascular panel shows elevated triglycerides, your formula may incorporate Ones' Heart Support blend alongside omega-3 actives.

This mirrors what the research actually recommends — not a generic ratio applied to everyone, but a context-specific approach based on biomarker data and health objectives. You can learn more about how personalized omega-3 dosing differs from standard supplements and why it matters for long-term outcomes.

For those managing stress alongside inflammation, understanding the clinical evidence for ashwagandha can also help frame how adaptogenic ingredients complement omega-3 protocols in a full formula.

Key Takeaways

• EPA and DHA have different biological roles. EPA is predominantly anti-inflammatory and mood-active; DHA is primarily structural, concentrated in the brain and retina.
• For depression and mood support, EPA-dominant ratios (≥2:1 EPA:DHA) are strongly supported by multiple meta-analyses, with formulas below 1.5:1 showing no significant antidepressant benefit in pooled data.
• For cognitive health and brain development, DHA-leaning formulas are more evidence-aligned, particularly for older adults and pregnant women.
• For cardiovascular health, both EPA and DHA reduce triglycerides, but high-dose pure EPA trials (REDUCE-IT) suggest additional cardioprotective mechanisms that blended formulas may not fully replicate.
• Your baseline omega-3 index, diet, and biomarkers should inform your ratio, not just your health goal — a blood-based assessment is the most reliable starting point.
• Ones personalizes omega-3 dosing and ratio emphasis based on your lab results and health goals, rather than applying a generic combined dose that may not match your actual needs.

Always consult a qualified healthcare provider before making significant changes to your supplement regimen, particularly if you have a diagnosed cardiovascular or psychiatric condition.